Multi-Center Clinical Study Result-Summary Meeting of Tubridge and Microcatheter Held in Shanghai

Recently, MicroPort NeuroTech (Shanghai) Co., Ltd. ("MicroPort NeuroTech") held its result-summary meeting of prospective, multi-center, randomized controlled clinical study for the products Tubridge Revascularization Device in Shanghai.

CHC 2013 Held in Beijing

In 2005, a Beijing based company formerly known as “Legend” acquired IBM’s venerable line of PC computers.

MicroPort Pioneer Balloon Dilatation Catheter Received CFDA Re-registration Certificate

Recently, Pioneer balloon dilatation catheter developed and manufactured by MicroPort received CFDA re-registration certificate.
Multi-Center Clinical Study Result-Summary
Meeting of Tubridge and Microcatheter
Held in Shanghai

Recently, MicroPort NeuroTech (Shanghai) Co., Ltd. ("MicroPort NeuroTech") held its result-summary meeting of prospective, multi-center, randomized controlled clinical study for the products Tubridge Revascularization Device in Shanghai. Mr. Zhiyong Xie, General Manager of MicroPort NeuroTech, and other 13 specialists from various neurologist centers participated in the meeting.

During the meeting, professors and experts actively discussed the clinical trial results including the integrity of the data and focal point for the next second-stage clinical trial. In addition, various professors from different hospitals talked about several difficult surgical cases. Dr. Jianmin Liu pointed out that Tubridge Revascularization Device is actually the first Flow diverter indicated for treatment of large aneurysms domestically. The device effectively addresses the recurrence rate problems from traditional stent-assisted coil embolization method. In addition, this is also the first prospective, multi-center, randomized controlled clinical study in the cerebral neuroscience field in China, which has a significant implication in the field. All the participating members affirmed their positive evaluation in the safety and efficacy features on this Tubridge Revascularization Device.

"Tubridge Revascularization Device is independently developed by MicroPort NeuroTech. It's the next generation neurovascular product for treating large cerebral aneurysm in China", said Mr. Zhiyong Xie, General Manager of MicroPort NeuroTech, "The clinical study is the largest one in the field of neurovascular-related disease in China and strictly followed through the international standard procedure. MicroPort NeuroTech will continuously making effort on pushing forward this project."

CHC 2013 Held in Beijing

China Heart Congress (CHC) 2013 (also known as "Fu Wai Meeting") was held from August 8 to 11, 2013 at the Beijing National Convention Center. This conference was jointly sponsored by the Chinese Medical Association and the National Cardiovascular Disease Center. The theme of this year is "Integration - Quality - Innovation". Experts and scholars around the world participated this academic exchange convention and engaged in discussion regarding the latest trend in the cardiovascular field and various challenges that cardiologists face in these days.

During the convention, MicroPort held its two luncheon symposiums named “Feel the Firehawk, Expand the Horizon” and “Stent Application in the Left Main Coronary Artery Disease” on 9th and 10th of August respectively. Professor Yaling Han from Shenyang Military Region General Hospital presided over the “Feel the Firehawk, Expand the Horizon” symposium. In addition, other physicians and doctors from major hospitals discussed the TARGET study report and analyzed two clinical cases from Firehawk stent. Other experts and professors also shared their skills and experiences during the symposium held by MicroPort on 10th of August.
MicroPort Pioneer Balloon Dilatation Catheter
Received CFDA Re-registration Certificate

Recently, Pioneer balloon dilatation catheter developed and manufactured by MicroPort received CFDA re-registration certificate.

MicroPort’s Pioneer is a balloon dilatation catheter featured with a fast switching system and excellent traceability and tracking performance. It is used during a minimally invasive non-surgical procedure commonly known as Percutaneous Transluminal Coronary Angioplasty (PTCA). The product provides further solutions for doctors and physicians during various surgeries treating complex lesions. One of the advantages of Pioneer is that any two Pioneer catheters with different specification can be perfectly matched and connected within the 6F guiding catheter. Pioneer is the first product that MicroPort introduced in China. Through the continuous product improvements, Pioneer has achieved the implant growth rate more than 30% in the past years. The newer registered Pioneer has added features including expanded hydrophilic coating which is designed to optimize trackability, crossability, and pushability during the surgery.